Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells

Journal of Immunology

Volumn 171, Issue 2, 2003, Pages 1070-1077

  Blanco, Belén ^a   Holliger, Phillip ^b   Vile, Richard G ^c   Álvarez Vallina, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; HYBRID PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0038108811     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.2.1070     Document Type: Article

References (42)

1. Pardoll, D. M. 1994. Tumour antigens: a new look for the 1990s. Nature 369:357.
2. Sogn, J. A. 1998. Tumor immunology: the glass is half full. Immunity 9:757.
3. Smyth, M. J., D. I. Godfrey, and J. A. Trapani. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2:293.
4. Ferrone, S., and F. M. Marincola. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16:487.
5. Seliger, B., M. J. Maeurer, and S. Ferrone. 1997. TAP off-tumors on. Immunol. Today 18:292.
6. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
7. Hellstrom, I., and K. E. Hellstrom. 1993. Tumor immunology: an overview. Ann. NY Acad. Sci. 690:24.
8. Alvarez-Vallina, L. 2000. Targeted cell immunotherapy of human cancer: a promising approach that is extending its initial cell and molecular scope. Tumor Targeting 4:225.
9. Segal, D. M., G. J. Weiner, and L. M. Weiner. 2001. Introduction: bispecific antibodies. J. Immunol. Methods 248:1.
10. Eshhar, Z. 1997. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 45:131.
11. Altenschmidt, U., D. Moritz, and B. Groner. 1997. Specific cytotoxic T lymphocytes in gene therapy. J. Mol. Med. 75:259.
12. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
13. Bolhuis, R. L., E. Sturm, and E. Braakman. 1991. T cell targeting in cancer therapy. Cancer Immunol. Immunother. 34:1.
14. 2 in ovarian carcinoma patients. Int. J. Cancer 66:477.
15. Weiner, L. M., J. I. Clark, D. B. Ring, and R. K. Alpaugh. 1995. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and FcγRIII. J Hematother 4:453.
16. Alvarez-Vallina, L. 2001. Genetic approaches for antigen-selective cell therapy. Curr. Gene Ther. 1:385.
17. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
18. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
19. L. Immunity 3:87.
20. Daniel, P. T., A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dorken, and A. Pezzutto. 1998. Immunotherapy of B-cell lymphoma with CD3 X 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 92:4750.
21. Renner, C., W. Jung, U. Sahin, R. Denfeld, C. Pohl, L. Trumper, F. Hartmann, V. Diehl, R. van Lier, and M. Pfreundschuh. 1994. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833.
22. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR-zeta/CD28 receptor. Nat. Biotechnol. 20:70.
23. Holliger, P., T. Prospero, and G. Winter. 1993. "Diabodies:" small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444.
24. Perisic, O., P. A. Webb, P. Holliger, G. Winter, and R. L. Williams. 1994. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217.
25. Nolan, K. F., C. O. Yun, Y. Akamatsu, J. C. Murphy, S. O. Leung, E. J. Beecham, and R. P. Junghans. 1999. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin. Cancer Res. 5:3928.
26. Hefta, L. J., F. S. Chen, M. Ronk, S. L. Sauter, V. Sarin, S. Oikawa, H. Nakazato, S. Hefta, and J. E. Shively. 1992. Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis. Cancer Res. 52:5647.
27. Holliger, P., O. Manzke, M. Span, R. Hawkins, B. Fleischmann, L. Qinghua, J. Wolf, V. Diehl, O. Cochet, G. Winter, et al. 1999. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 X anti-CEA bispecific diabodies and B7 X anti-CEA bispecific fusion proteins. Cancer Res. 59:2909.
28. Sanz, L., P. Kristensen, B. Blanco, S. Facteau, S. J. Russell, G. Winter, and L. Álvarez-Vallina. 2002. Inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 9:1049.
29. Blanco, B., P. Holliger, and L. Alvarez-Vallina. 2002. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Ther. 9:275.
30. Alvarez-Vallina, L., and R. E. Hawkins. 1996. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26:2304.
31. Chester, K. A., R. H. Begent, L. Robson, P. Keep, R. B. Pedley, J. A. Boden, G. Boxer, A. Green, G. Winter, O. Cochet, et al. 1994. Phage libraries for generation of clinically useful antibodies. Lancet 343:455.
32. Salmeron, A., F. Sanchez-Madrid, M. A. Ursa, M. Fresno, and B. Alarcon. 1991. A conformational epitope expressed upon association of CD3-ε with either CD3-δ or CD3-γ is the main target for recognition by anti-CD3 monoclonal antibodies. J. Immunol. 147:3047.
33. Lozzio, B. B., C. B. Lozzio, E. G. Bamberger, and A. S. Feliu. 1981. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 166:546.
34. Beerli, R. R., W. Wels, and N. E. Hynes. 1994. Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochim. Biophys. Acta 204:666.
35. Sussman, J. J., J. S. Bonifacino, J. Lippincott-Schwartz, A. M. Weissman, T. Saito, R. D. Klausner, and J. D. Ashwell. 1988. Failure to synthesize the T cell CD3-ζ chain: structure and function of a partial T cell receptor complex. Cell 52:85.
36. Klausner, R. D., J. Lippincott-Schwartz, and J. S. Bonifacino. 1990. The T cell antigen receptor: insights into organelle biology. Annu. Rev. Cell. Biol. 6:403.
37. Jost, C. R., J. A. Titus, I. Kurucz, and D. M. Segal. 1996. A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol. Immunol. 33:211.
38. Brüsselbach, T., T. Korn, T. Völkel, R. Müller, and R. E. Konterman. 1999. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting 4:115.
39. Lanzavecchia, A., and D. Scheidegger. 1987. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 17:105.
40. Yokota, T., D. E. Milenic, M. Whitlow, and J. Schlom. 1992. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:3402.
41. Begent, R. H., M. J. Verhaar, K. A. Chester, J. L. Casey, A. J. Green, M. P. Napier, L. D. Hope-Stone, N. Cushen, P. A. Keep, C. J. Johnson, et al. 1996. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2:979.
42. FitzGerald, K., P. Holliger, and G. Winter. 1997. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng. 10:1221.